Clinical trial NCT06572631: Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
Official title: Phase 1b Expansion Study of Multi-Antigen Specific CD8+ T Cells After Decitabine-enhanced Lymphodepletion: An Adoptive Cellular Therapy for Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From Matched HLA Donors
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Recurrent Acute Myeloid Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome
Lead sponsor: City of Hope Medical Center
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2024-08-27
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase I trial tests the safety, side effects and best dose of NEXI-001 when given with decitabine and lymphodepleting chemotherapy in treating patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory) following an allogeneic hematopoietic cell transplantation from a matched donor. NEXI-001 is a type of chimeric antigen receptor T cell therapy in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Lymphodepleting chemotherapy, with fludarabine and cyclophosphamide, helps kill cancer cells in the body and helps prepare the body for the new CAR-T cells. Giving NEXI-001 with decitabine and lymphodepleting chemotherapy may be safe and tolerable in treating patients with relapsed or refractory AML or MDS following an allogeneic hematopoietic cell transplantation from a matched donor.

Detailed description: PRIMARY OBJECTIVES:

I. Characterize the safety of allogeneic CD8+ leukemia-associated antigens specific T cells NEXI-001 (NEXI-001) combined with decitabine.

II. Determine the recommended phase 2 dose (RP2D) for NEXI-001 T cells combined with decitabine.

SECONDARY OBJECTIVES:

I. Investigate the preliminary anti-leukemic activity of NEXI-001 T cells combined with decitabine based on:

Ia. Complete response (CR) rate; Ib. Overall response rate (ORR); Ic. Median duration of response; Id. 1-year overall survival (OS); Ie. 1-year progression-free survival (PFS). II. Cumulative incidence of acute graft-versus-host disease (aGVHD) of grades 2-4 and 3-4 at day 100 post first infusion of NEXI-001.

III. Cumulative incidence of chronic graft-versus-host disease (cGVHD) of all grades at 1 year post first infusion of NEXI-001.

IV. Characterize the T cells in the NEXI-001 product by immunophenotype and tumor antigen specificity.

V. Characterize NEXI-001 T cells in peripheral blood (PB) and bone marrow (BM) by immunophenotype and tumor antigen specificity.

VI. Expansion and persistence of NEXI-001 T cells in PB and BM.

EXPLORATORY OBJECTIVES:

I. Evaluate the effect of the following factors on the safety and efficacy of NEXI-001 T cells combined with decitabine:

Ia. NEXI-001 T-cell immunophenotype; Ib. Persistence of NEXI-001 T cells in PB and BM; Ic. Blood levels of the antigen-specific NEXI-001 T cells; Id. Biomarkers of activation, proliferation, and exhaustion of T cells; Ie. The expression of tumor associated antigen (TAAs) and checkpoint molecules on AML blasts.

OUTLINE: This is a dose-escalation study of decitabine in combination with NEXI-001, fludarabine and cyclophosphamide.

DONOR: Donors undergo leukapheresis on study.

PATIENTS: Patients may receive bridging therapy per standard of care ≥ 14 days prior to the start of cycle 1. Patients receive decitabine intravenously (IV) over 1 hour once per day (QD) on day -3, -5 or -10 to day -1, lymphodepletion chemotherapy with fludarabine IV over 30 minutes QD and cyclophosphamide IV over 60 minutes QD on day -5 to -3 and then receive NEXI-001 IV over 30 minutes QD on days 1, 8 and 15 of cycle 1. Cycles repeat every 33 or 38 days in the absence of disease progression or unacceptable toxicity. If NEXI-001 cells remain and treatment criteria are met, patients may receive and additional cycle of decitabine IV over 1 hour QD on day -5 to -1 and NEXI-001 IV QD on days 1, 8 and 15 in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography (ECHO) during screening, bone marrow aspirate and/or bone marrow biopsy, positron emission tomography (PET)/computed tomography (CT) scan or magnetic resonance imaging (MRI) and blood sample collection throughout the study.

After completion of study treatment, patients are followed up within 30 days and every 3 months for up to 1 year.

Eligibility criteria: Inclusion Criteria:

* PARTICIPANT: Documented informed consent of the participant and/or legally authorized representative and documented informed consent of the donor
* PARTICIPANT: Agreement to allow the use of archival tissue from diagnostic tumor biopsies (if unavailable, exceptions may be granted with study principal investigator \[PI\] approval)
* PARTICIPANT: Age: ≥ 18 years
* PARTICIPANT: Eastern Cooperative Oncology Group (ECOG) ≤ 1 or Karnofsky performance score (KPS) ≥ 70
* PARTICIPANT: Confirmed diagnosis of AML/MDS that has relapsed after or is refractory to an allogeneic hematopoietic cell transplantation (HCT) from a matched donor.

  * Refractory - failure to achieve a complete response minimal residual disease (CRMRD) (-) by multicolor flow cytometry (MFC) or reverse transcription polymerase chain reaction (RT qPCR)
  * Relapse - detection of clonal abnormal myeloid blasts by morphology (morphologic relapse) or by MFC, or RT-qPCR analysis (MRD\[+\] relapse) after achieving a CRMRD(-) induced by an allogeneic HCT or maintained by allogeneic HCT administered as consolidation therapy.

Note: Patients who meet the protocol definition of relapse/refractory (r/r) AML/MDS at screening and subsequently achieve a CRMRD(-) response status following protocol-specified bridging therapy will remain eligible to continue participation in this study

* PARTICIPANT: At least 100 days post allogeneic HCT
* PARTICIPANT: Donor match at 8 out of 8 loci for human leucocyte antigen (HLA) -A, -B, -C, and -DRB1 (each typed at high resolution by deoxyribonucleic acid \[DNA\]-based methods)
* PARTICIPANT: Expression of HLA-A\*0201 as determined by high resolution sequence-based typing methods
* PARTICIPANT: Total bilirubin ≤ 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) (to be performed within 28 days of consenting)
* PARTICIPANT: Aspartate aminotransferase (AST) ≤ 2.5 x ULN (to be performed within 28 days of consenting)
* PARTICIPANT: Alanine aminotransferase (ALT) ≤ 2.5 x ULN (to be performed within 28 days of consenting)
* PARTICIPANT: Serum creatinine \< 1.5 mg/dL or creatinine clearance of ≥ 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (to be performed within 28 days of consenting)
* PARTICIPANT: Left ventricular ejection fraction (LVEF) ≥ 50% Note: To be performed before the first dose of lymphodepletion chemotherapy
* PARTICIPANT: If able to perform pulmonary function tests: Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and diffuse lung capacity for carbon monoxide (DLCO) (diffusion capacity) ≥ 50% of predicted (corrected for hemoglobin) (to be performed within 28 days of consenting)
* PARTICIPANT: If unable to perform pulmonary function tests: Oxygen (O2) saturation \> 92% on room air (to be performed within 28 days of consenting)
* PARTICIPANT: Seronegative for HIV antigen/antibody (Ag/Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin \[RPR\]) (to be performed within 28 days of consenting)

  * If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed. OR
  * If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable
* PARTICIPANT: Women of childbearing potential (WOCBP): Negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (to be performed within 28 days of consenting)
* PARTICIPANT: Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 3 months after the completion of the last cycle of protocol therapy.

  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)
* DONOR: The identified donor must be the donor whose stem cells were used for the research participant's allo HCT
* DONOR: The donor's hematocrit value is ≥ 35%
* DONOR: The donor's platelet count is \> 100,000 per microliter
* CRITERIA TO PROCEED TO START OF CYCLE 1: NEXI-001 product is released from manufacturing with a certificate of analysis (COA)
* CRITERIA TO PROCEED TO START OF CYCLE 1: Bone marrow aspirate and bone marrow biopsy within one week prior to treatment for baseline disease status (all disease statuses are eligible to proceed) and correlative studies
* CRITERIA TO PROCEED TO START OF CYCLE 1: T-cell chimerism ≥ 50% to donor by polymerase chain reaction (PCR) analysis
* CRITERIA TO PROCEED TO START OF CYCLE 1: Fully recovered to ≤ grade 1 from non-hematologic acute toxic effects (except alopecia) from prior anti-cancer therapy
* CRITERIA TO PROCEED TO START OF CYCLE 1: Total bilirubin ≤ 1.5 X ULN (unless has Gilbert's disease) (to be performed within 2 days prior to start of cycle therapy)
* CRITERIA TO PROCEED TO START OF CYCLE 1: AST =\< 2.5 x ULN (to be performed within 2 days prior to start of cycle therapy)
* CRITERIA TO PROCEED TO START OF CYCLE 1: ALT =\< 2.5 x ULN (to be performed within 2 days prior to start of cycle therapy)
* CRITERIA TO PROCEED TO START OF CYCLE 1: Serum creatinine \< 1.5 mg/dL or creatinine clearance of ≥ 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula (to be performed within 2 days prior to start of cycle therapy)
* CRITERIA TO PROCEED TO START OF CYCLE 1: If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin (PT) ≤ 1.5 x ULN. If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants (to be performed within 2 days prior to start of cycle therapy)
* CRITERIA TO PROCEED TO START OF CYCLE 1: If not receiving anticoagulants: Activated partial thromboplastin Time (aPTT) ≤ 1.5 x ULN. If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants (to be performed within 2 days prior to start of cycle therapy)
* CRITERIA TO PROCEED TO START OF CYCLE 1: Left ventricular ejection fraction (LVEF) ≥ 50% (to be performed within 2 days prior to start of cycle therapy)

  * Note: To be performed before the first dose of LD chemotherapy
* CRITERIA TO PROCEED TO START OF CYCLE 1: Corrected QT (QTc) ≤ 480 ms (to be performed within 2 days prior to start of cycle therapy)
* CRITERIA TO PROCEED TO START OF CYCLE 1: O2 saturation \> 92% on room air (to be performed within 2 days prior to start of cycle therapy)
* CRITERIA TO PROCEED TO START OF CYCLE 1: Women of childbearing potential (WOCBP): Negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (to be performed within 2 days prior to start of cycle therapy)
* CRITERIA TO PROCEED TO START OF CYCLE 1: Investigational drugs or devices within 30 days prior to start of cycle 1 therapy
* NEXI-001 INCLUSION CRITERIA: Total bilirubin ≤ 2.5 X ULN (unless has Gilbert's disease) (to be performed within 1 days prior to NEXI-001 infusion)
* NEXI-001 INCLUSION CRITERIA: AST =\< 3 x ULN (to be performed within 1 days prior to NEXI-001 infusion)
* NEXI-001 INCLUSION CRITERIA: Serum creatinine \< 2 mg/dL (to be performed within 1 days prior to NEXI-001 infusion)
* NEXI-001 INCLUSION CRITERIA: O2 saturation \> 92% on room air (to be performed within 1 days prior to NEXI-001 infusion)
* CRITERIA TO PROCEED TO CYCLE 2: Patient has achieved a response of at least stable disease
* CRITERIA TO PROCEED TO CYCLE 2: ANC must be at least 1,000/uL and platelets at least 50,000/uL to begin decitabine
* CRITERIA TO PROCEED TO CYCLE 2: Patient has not experienced a ≥ grade 3 NEXI-001-related nonhematological AE that did not resolve to ≤ grade 2 within 72 hours

Exclusion Criteria:

* PARTICIPANT: Patients who have had 2 prior allogeneic (allo) HCTs
* PARTICIPANT: Patients who have received more than 3 anti-leukemic treatments regimens since their allo HCT
* PARTICIPANT: Vaccination with a live virus within six months prior to study treatment.

  * Inactivated influenza vaccination is allowed
* PARTICIPANT: Active acute or chronic GVHD
* PARTICIPANT: Known hypersensitivity to any component of the NEXI-001 T-cell product or fludarabine, cyclophosphamide, decitabine, or tocilizumab
* PARTICIPANT: Clinically significant uncontrolled illness
* PARTICIPANT: A second primary malignancy that has not been in remission for \> 2 years. Exceptions include the following resected lesions:

  * Non-melanoma skin cancer.
  * Carcinoma in situ.
  * Squamous intraepithelial lesions on Pap smear.
  * Localized prostate cancer (Gleason score \< 6).
  * Melanoma in situ
* PARTICIPANT: Females only: Pregnant or breastfeeding
* PARTICIPANT: Clinically significant cardiovascular disease:

  * Myocardial infarction or unstable angina within 6 months prior to the start of lymphodepleting (LD) chemotherapy.
  * Cerebral vascular accident or a transient ischemic attack within 6 months prior to the start of LD chemotherapy.
  * Clinically significant cardiac arrhythmia
  * Uncontrolled hypertension
  * Congestive heart failure (New York Heart Association Class III or IV)
  * Pericarditis or clinically significant pericardial effusion
  * Myocarditis
* PARTICIPANT: History of autoimmune disease resulting in end organ injury or requiring systemic immunosuppression or systemic disease modifying therapy within 2 years prior to enrollment.

  * Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone remain eligible.
  * Patients with controlled type 1 diabetes mellitus on a stable insulin regimen remain eligible
* PARTICIPANT: Major trauma or major surgery within 4 weeks of enrollment
* PARTICIPANT: Dementia or altered mental status that precludes understanding the informed consent form
* PARTICIPANT: History of seizures or other chronic clinically significant neurologic disorders.

  * Patients with well-controlled seizures on anti-seizure medication without a seizure episode for ≥ 6 months remain eligible
* PARTICIPANT: Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
* PARTICIPANT: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
* DONOR: The donor is pregnant or breastfeeding at the time of requested donation
* DONOR: The donor had granulocyte colony stimulating factor (G-CSF) administered within one month, prior to leukapheresis
* DONOR: The donor has an active bacterial or fungal infection, which is currently not responding to antimicrobial treatment
* CRITERIA TO PROCEED TO START OF CYCLE 1: Other anti-leukemic (bridging) therapies within 14 days of start of cycle 1 therapy
* CRITERIA TO PROCEED TO START OF CYCLE 1: Patients receiving systemic corticosteroid (\> 20 mg/day prednisone equivalent) or any other immunosuppressant agents at the time of initiation of LD chemotherapy. Intermittent topical, inhaled, or intranasal corticosteroids are allowed
* CRITERIA TO PROCEED TO START OF CYCLE 1: Active acute or chronic GVHD (Note: must have resolved by the time of initiation of cycle 1 of therapy
* CRITERIA TO PROCEED TO START OF CYCLE 1: Active or uncontrolled infection requiring antibiotics by the time LD chemotherapy is scheduled. Prophylactic and ongoing therapy for prior controlled infection is allowed
* CRITERIA TO PROCEED TO START OF CYCLE 1: Females only: Pregnant or breastfeeding
* CRITERIA TO PROCEED TO START OF CYCLE 1: Clinically significant cardiovascular disease:

  * Myocardial infarction or unstable angina within 6 months prior to the start of LD chemotherapy
  * Cerebral vascular accident or a transient ischemic attack within 6 months prior to the start of LD chemotherapy
  * Clinically significant cardiac arrhythmia
  * Uncontrolled hypertension
  * Congestive heart failure (New York Heart Association Class III or IV)
  * Pericarditis or clinically significant pericardial effusion
  * Myocarditis
  * History of seizures or other chronic clinically significant neurologic disorders. Patients with well-controlled seizures on anti-seizure medication without a seizure episode for ≥ 6 months remain eligible
* CRITERIA TO PROCEED TO START OF CYCLE 1: Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
* NEXI-001 EXCLUSION CRITERIA: Patient has no evidence of NEXI-001-related nonhematological adverse events (AEs), e.g. cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS)
* NEXI-001 EXCLUSION CRITERIA: Patient has not developed any of the exclusion criteria for treatment
* CRITERIA TO PROCEED TO CYCLE 2: Patient has not developed any of the exclusion criteria for treatment

Primary outcomes:
measure: Incidence of adverse events (AEs)
timeFrame: Up to 1.5 years
measure: Dose limiting toxicity
timeFrame: Up to completion of cycle 1
Secondary outcomes:
measure: Overall response
timeFrame: Up to 1.5 years
measure: Complete response
timeFrame: Up to 1.5 years
measure: Duration of response
timeFrame: From the starting date of response to the date of disease progression, up to 1.5 years
measure: Progression free survival
timeFrame: From starting study therapy to the first observation of disease progression or date of death, whichever comes first, up to 1.5 years
measure: Overall survival
timeFrame: From starting study therapy to the date of death, up to 1.5 years
measure: Determine the immunophenotype of NEXI-001 T cells
timeFrame: Up to 1.5 years
measure: Incidence of acute GVHD
timeFrame: Up to 1.5 years
measure: Incidence of chronic GVHD
timeFrame: Up to 1.5 years
measure: Persistence/antigen specificity of NEXI-001 T cells
timeFrame: Up to 1.5 years
Other outcomes:
Locations:
Study officials:
affiliation: City of Hope Medical Center
name: Monzr M Al Malki, MD
role: PRINCIPAL_INVESTIGATOR
References: